These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15962532)

  • 41. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
    Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
    Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HHS-CDC news: Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--US, 1998-2003.
    Ann Pharmacother; 2005 Nov; 39(11):1967-8. PubMed ID: 16219891
    [No Abstract]   [Full Text] [Related]  

  • 43. Prevenar vaccination: review of the global data, 2006.
    Center KJ
    Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
    Giele C; Moore H; Bayley K; Harrison C; Murphy D; Rooney K; Keil AD; Lehmann D
    Vaccine; 2007 Mar; 25(13):2379-84. PubMed ID: 17064825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measuring immunization coverage among preschool children: past, present, and future opportunities.
    Salmon DA; Smith PJ; Navar AM; Pan WK; Omer SB; Singleton JA; Halsey NA
    Epidemiol Rev; 2006; 28():27-40. PubMed ID: 16740586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expected benefits of pneumococcal vaccination in Canadian infants and children < 5 years old.
    Can Commun Dis Rep; 2006 Mar; 32(5):45-54. PubMed ID: 16649291
    [No Abstract]   [Full Text] [Related]  

  • 47. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.
    Metlay JP; Fishman NO; Joffe M; Edelstein PH
    Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
    Toltzis P; Jacobs MR
    Infect Dis Clin North Am; 2005 Sep; 19(3):629-45. PubMed ID: 16102653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention.
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):189-209. PubMed ID: 19296419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    Hartwig NG; Rümke HC
    Ned Tijdschr Geneeskd; 2007 Nov; 151(46):2592; author reply 2593. PubMed ID: 18074732
    [No Abstract]   [Full Text] [Related]  

  • 53. Pneumococcal vaccination programme in over 65s and at-risk groups: the Dumfries and Galloway experience.
    Breen D
    Commun Dis Public Health; 2003 Sep; 6(3):228-30. PubMed ID: 14708273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunization and the prevention of influenza and pneumococcal disease in people with diabetes.
    American Diabetes Association
    Diabetes Care; 2000 Jan; 23 Suppl 1():S91-3. PubMed ID: 12017693
    [No Abstract]   [Full Text] [Related]  

  • 55. The National Immunization Strategy.
    Can Commun Dis Rep; 2004 Aug; 30(15):136-8. PubMed ID: 15315241
    [No Abstract]   [Full Text] [Related]  

  • 56. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 57. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 58. I had my pneumococcal shot at age 65. Do I need to be revaccinated?
    Mayo Clin Womens Healthsource; 2009 Mar; 13(3):8. PubMed ID: 19179935
    [No Abstract]   [Full Text] [Related]  

  • 59. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine.
    Winther TN; Kristensen TD; Kaltoft MS; Konradsen HB; Knudsen JD; Høgh B
    Acta Paediatr; 2009 Feb; 98(2):328-31. PubMed ID: 18983440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.